From compound selection to preclinical data.
Select a DempoChem research compound and move it through one coordinated path into an agreed in vitro ADME/DMPK, in vivo PK/PD, or disease-model study—from material planning and direct laboratory delivery to the final report and data package.
Fewer handoffs. A clearer route to the data.
Instead of managing a chemical supplier, international shipment, and laboratory separately, work through one project connection from compound selection onward.
- 01
Select the compound
Start with a DempoChem research compound or discuss a sourcing requirement with our team.
- 02
Align the study
Define the research question, in vitro or in vivo model, DMPK or PK/PD endpoints, and expected outputs.
- 03
Direct laboratory handoff
Once confirmed, the compound can move directly to the agreed partner laboratory for execution.
- 04
Receive the data
Work through one project contact and receive the agreed study report and data package.
Chemistry and study execution, connected.
From in vitro ADME screening and DMPK strategy to in vivo pharmacology and bioanalysis, each request is reviewed around the compound, model, endpoints, and expected outputs before the study is confirmed.
Material readiness
Compound supply, required quantity, purity, and available batch documentation.
In vitro ADME & DMPK
Solubility, permeability, plasma protein binding, metabolic stability, CYP, and transporter profiling.
In vivo PK/PD & efficacy
Bioavailability, exposure, tissue distribution, tolerability, efficacy, and related pharmacology endpoints.
Study reporting
One project contact for execution updates, the final report, and the agreed data package.
Specific models, study scope, timelines, and deliverables are confirmed during technical review.
Popular preclinical models for your next study.
Explore frequently requested in vitro models, in vivo models, and disease models across oncology, immuno-oncology, metabolic disease, human-relevant systems, advanced modalities, and other translational research areas.
Oncology & immuno-oncology
ADCs, bispecific and multispecific antibodies
Cell line-derived xenograft (CDX) models, patient-derived xenograft (PDX) models, syngeneic tumor models, PBMC- or CD34+ HSC-humanized mouse models, human immune-checkpoint knock-in models, orthotopic tumor models, and metastatic models.
Human-relevant in vitro systems
New Approach Methodologies (NAMs) and translational screening
Patient-derived organoid (PDO) models, 3D co-culture models, organ-on-chip models, and other microphysiological systems (MPS).
Metabolic disease
Obesity, GLP-1, and MASH programs
C57BL/6 diet-induced obesity (DIO) models, ob/ob and db/db obesity models, GLP-1R-humanized models, and CDAA- or HFHC diet-induced MASH models with PK/PD and biomarker endpoints.
Advanced modalities
ASO, siRNA, and mRNA therapeutics, including LNP-enabled delivery; cell and gene therapies; radiopharmaceutical and RDC programs
Biodistribution, tissue exposure, pharmacology, and modality-specific preclinical model support aligned with the delivery system and intended biological readout.
Our support extends beyond the examples above. Share your compound, therapeutic area, and study objective, and we can review additional models, species, donors, tumor types, study designs, and endpoints with our partner laboratories.
Already know what you want to study?
Share the compound, research objective, and intended in vitro or in vivo model. We will review material readiness, DMPK or pharmacology endpoints, and study feasibility together.